You are here: Home » Companies » News
Business Standard

Bharat Biotech to begin trials of intranasal vaccine for Covid in Feb-Mar

The Phase-1 trials will be conducted in Saint Louis University's Vaccine and Treatment Evaluation Unit

Topics
Bharat Biotech | Coronavirus Vaccine

Press Trust of India  |  Hyderabad 

bharat biotech, vaccine, coronavirus, covid-19, pharma, drugs, medicine
According to him, keeping several issues in mind BharatBiotechtied up withWashingtonUniversitySchool of Medicine for the single doseintranasalvaccine for Covid-19.

Buoyed by theEmergency Use Authorisation approval from theDrug Controller General of India (DCGI)for its Covid-19 vaccine Covaxin,has said Phase-1 clinical trials of its new intranasal antidote for the killer virus will begin during February-March this year.

Besides Covaxin, BharatBiotechhas been actively working on developing another vaccine, for which it tied up with Washington UniversitySchool of Medicine in St Louis for the novel "chimp-adenovirus" (Chimpanzee adenovirus), a single doseintranasalvaccine for Covid-19.

"BBV154 (intranasal Covid-19 vaccine), preclinical testing has been completed for toxicology, immunogenicity and challenge studies. These studies have been conducted in the USA and India. Phase I human clinical trials will commence during Feb-March 2021," an email reply from the city-based vaccine maker told P T I.

Phase I human clinical trials will be conducted in India, added.

The Phase-1 trials will be conducted in Saint Louis University's Vaccine and Treatment Evaluation Unit, the company sources said adding owns the rights to distribute the vaccine in all markets except USA, Japan and Europe.

Krishna Ella, Chairman ofBharatBiotechhad earlier said the company is focusing on the intranasal vaccine as the existing vaccinesrequire two dose intramuscular injections and a country like India needs 2.6 billionsyringes and needleswhich may add up to pollution.

An intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive, he had said.

"One drop of vaccine in each of the nostrils is sufficient," he had said.

According to him, keeping several issues in mind BharatBiotechtied up withWashingtonUniversitySchool of Medicine for the single doseintranasalvaccine for Covid-19.

He had said Bharat Biotech envisions that it would scale this vaccine to one billion doses, translating into equal number of individuals being vaccinated receiving a single-dose regimen.

BharatBiotech, upon obtainingrequired regulatory approval, will pursue further stages of clinical trials in India and undertake large scale manufacture of the vaccine at its GMP (good manufacturing practice) facility located in Genome Valley, here, the company had earlier said.

The intranasal vaccine candidate has shown unprecedented levels of protection in mice studies and the technology and data having been already published in the prestigious scientific journal 'Cell' and in an editorial in 'Nature', the company had said.

Bharat Biotech has successfully completed enrollment of 25,800 volunteers for the Phase-3 trials of its Covid-19 vaccine Covaxin.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, January 08 2021. 23:05 IST
RECOMMENDED FOR YOU
.